Literature DB >> 10408860

'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression.

J R MacDougall1, M R Bani, Y Lin, R J Muschel, R S Kerbel.   

Abstract

Although it is generally accepted that proteolytic degradation is an important mechanism used by malignant cells in the process of metastasis, comparatively little is known about the regulation of molecules responsible for proteolysis and how they become de-regulated during human tumour progression. Using a genetically related pair of human melanoma cell lines, derived from the same patient at different stages of disease, we analysed differences in the cytokine-mediated regulation of gelatinase B (MMP-9), an enzyme thought to play an important role in cellular invasiveness, and TIMP-1, a physiological inhibitor of this enzyme. Whereas the advanced stage (i.e. metastatic) partner of this pair (WM 239) could produce gelatinase B upon induction with interleukin (IL)-1beta or tumour necrosis factor alpha (TNF-alpha), the early stage (i.e. primary) partner (WM 115) could not. In sharp contrast, we found that TIMP-1 displayed an opposite pattern of induction in these cell lines. Specifically, the early stage cell line, WM 115, demonstrated a marked increase in the production of TIMP-1 when treated with IL-1beta or TNF-alpha whereas the advanced cell line, WM 239, showed no such increase. Treatment with the DNA demethylating agent, 2-deoxy-5-azacytidine, resulted in a marked up-regulation of both gelatinase B and TIMP-1 in both cell lines. It was further found that constitutive overexpression of gelatinase B in WM 239 cells and an additional melanoma cell line (MeWo), derived from a metastatic lesion, was able to greatly enhance lung colonization in an experimental metastasis assay while we did not observe differences in tumorigenicity. From these results we conclude that an altered responsiveness of gelatinase B and TIMP-1 to induction by similar agents is associated with disease progression in human melanoma and that this altered responsiveness can have consequences to the aggressive nature of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408860      PMCID: PMC2362325          DOI: 10.1038/sj.bjc.6690385

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  60 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  MT1-MMP on the cell surface causes focal degradation of gelatin films.

Authors:  M P d'Ortho; H Stanton; M Butler; S J Atkinson; G Murphy; R M Hembry
Journal:  FEBS Lett       Date:  1998-01-09       Impact factor: 4.124

3.  Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta.

Authors:  T A Mustoe; G F Pierce; A Thomason; P Gramates; M B Sporn; T F Deuel
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

4.  MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes.

Authors:  T H Vu; J M Shipley; G Bergers; J E Berger; J A Helms; D Hanahan; S D Shapiro; R M Senior; Z Werb
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

5.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.

Authors:  I E Collier; S M Wilhelm; A Z Eisen; B L Marmer; G A Grant; J L Seltzer; A Kronberger; C S He; E A Bauer; G I Goldberg
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

6.  Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors.

Authors:  G S Herron; M J Banda; E J Clark; J Gavrilovic; Z Werb
Journal:  J Biol Chem       Date:  1986-02-25       Impact factor: 5.157

7.  Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site.

Authors:  M Suzuki; G Raab; M A Moses; C A Fernandez; M Klagsbrun
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

8.  Thin malignant melanomas with regression and metastases.

Authors:  S G Ronan; A M Eng; H A Briele; N N Shioura; T K Das Gupta
Journal:  Arch Dermatol       Date:  1987-10

9.  Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo.

Authors:  J P Witty; S McDonnell; K J Newell; P Cannon; M Navre; R J Tressler; L M Matrisian
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

10.  Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor.

Authors:  D R Edwards; G Murphy; J J Reynolds; S E Whitham; A J Docherty; P Angel; J K Heath
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  13 in total

1.  Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression.

Authors:  M E Kupferman; M E Fini; W J Muller; R Weber; Y Cheng; R J Muschel
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  Biological stimuli and biomolecules in the assembly and manipulation of nanoscale polymeric particles.

Authors:  Lyndsay M Randolph; Miao-Ping Chien; Nathan C Gianneschi
Journal:  Chem Sci       Date:  2012-05-01       Impact factor: 9.825

3.  Controlling and switching the morphology of micellar nanoparticles with enzymes.

Authors:  Ti-Hsuan Ku; Miao-Ping Chien; Matthew P Thompson; Robert S Sinkovits; Norman H Olson; Timothy S Baker; Nathan C Gianneschi
Journal:  J Am Chem Soc       Date:  2011-04-04       Impact factor: 15.419

4.  Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation.

Authors:  Tatiana I Ricca; Gangning Liang; Ana Paula M Suenaga; Sang W Han; Peter A Jones; Miriam G Jasiulionis
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

5.  Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.

Authors:  Antonietta Silini; Carmen Ghilardi; Camilla Ardinghi; Sergio Bernasconi; Paolo Oliva; Fabio Carraro; Antonella Naldini; Maria Rosa Bani; Raffaella Giavazzi
Journal:  Clin Exp Metastasis       Date:  2009-12-20       Impact factor: 5.150

6.  Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival.

Authors:  Ferhat Ozden; Caner Saygin; Didem Uzunaslan; Bulent Onal; Haydar Durak; Hilal Aki
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-25       Impact factor: 4.553

Review 7.  Epigenetic regulation of mmp-9 gene expression.

Authors:  Marilyne Labrie; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2012-11-27       Impact factor: 9.261

8.  The lncRNA SLNCR1 Mediates Melanoma Invasion through a Conserved SRA1-like Region.

Authors:  Karyn Schmidt; Cailin E Joyce; Frank Buquicchio; Adam Brown; Justin Ritz; Robert J Distel; Charles H Yoon; Carl D Novina
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

9.  Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Blair R Szymczyna; Karim Essani
Journal:  Med Oncol       Date:  2017-06-07       Impact factor: 3.738

10.  Elastin-derived peptides enhance melanoma growth in vivo by upregulating the activation of Mcol-A (MMP-1) collagenase.

Authors:  J Devy; L Duca; B Cantarelli; D Joseph-Pietras; A Scandolera; A Rusciani; L Parent; J Thevenard; S Brassart Pasco; M Tarpin; L Martiny; L Debelle
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.